- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00184054
Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia
Phase II Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-APL Acute Myelogenous Leukemia
This clinical research study is for patients with acute myelogenous leukemia (in short AML) that did not respond to previous treatment or unable to receive chemotherapy.
Arsenic has been used as a drug for many centuries. While arsenic containing drugs were used in the past for cancer treatments, the major use of arsenic in western countries has been for the treatment of uncommon tropical illnesses, such as sleeping sickness. Recently, some new information suggests that arsenic in a form called arsenic trioxide may also be useful to treat some cancers of the blood, such as leukemia, lymphoma and myeloma. Studies from China and the USA showed that patients with a type of blood cancer called acute promyelocytic leukemia, whose disease failed to respond to other treatments, responded very well to arsenic trioxide. Studies done in laboratories in the United States have shown that arsenic can kill AML cells growing in culture dishes.
Ascorbic acid (vitamin C), a natural supplement in our diet, has long been involved with cancer prevention. Laboratory tests have shown that although arsenic trioxide by itself can kill AML cells in the test tube, when vitamin C is added to arsenic trioxide in a test tube, the death of the leukemia cells increases significantly.
The purpose of this study is to find out if the combination of arsenic trioxide (Trisenox) and ascorbic acid is effective in the treatment of patients who have AML. The second purpose is to study how the two drugs affect cells in the laboratory. Samples from the blood and bone marrow (the part of the body that makes blood cells) will be collected, at specific times during treatment, in order to study them in the laboratory. By studying blood and marrow cells, researchers hope to learn the mechanisms by which the drugs work.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90032
- USC/Norris Comprehensive Cancer Center and Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of non-APL AML (FAB subtypes M0 - M7 but excluding M3) confirmed by myeloperoxidase stain and/or flow cytometry.
For patients of age 18 or older - only refractory or relapsed AML will be included. Refractory disease is defined as newly diagnosed patients who fulfill ONE of the following criteria:
- Patient aged 60 years or younger, who have failed to achieve a complete remission after at least two cycles of front line induction chemotherapy.
- Patients of any age who have AML, that is post myelodysplastic syndrome (MDS), who failed to achieve a complete remission after at least one cycle of front line induction chemotherapy.
- Patients aged 60 years or older who failed to achieve a complete remission after at least one cycle of front line induction chemotherapy.
- Newly diagnosed patients aged 55 or older who will not receive intensive anti-leukemia chemotherapy can also be enrolled.
- Post-myelodysplasia AML and secondary AML are included.
- Stem cell transplantation failures are included.
- Karnofsky performance status greater or equal to 50%.
- Adequate renal function (creatinine < 1.5 x ULN or creatinine clearance > 60 ml/min) and hepatic function (transaminases < 2.5 x ULN, serum total bilirubin < 3 mg/dl).
- Females of childbearing potential must have a negative serum pregnancy test prior to enrollment on the study, and both women and men must use an effective birth control method while on the study.
- Signed consent.
Exclusion Criteria:
Newly diagnosed patients older than age 55 who:
- Refuse chemotherapy when their treating physician recommends standard anti-leukemia induction chemotherapy.
- Have a Karnofsky performance status of greater or equal to 70%, aged < 75 years and has no prior myelodysplastic syndrome.
- Have a risk/benefit ratio that gives their treating physician good reason for administration of standard anti-leukemia induction chemotherapy.
- Patients who have already been treated with arsenics.
- CML in blastic crisis.
- Patients with cardiopathies including recurrent supraventricular arrhythmia and any type of sustained ventricular arrhythmia or conduction block (A-V block grade II or III, LBBB).
- Patients with HIV.
- Pregnant or breastfeeding women.
- QT interval > 460 msec in the presence of serum potassium > 4.0 mEq/L and magnesium > 1.8 mg/dL.
- Pre-existing neurotoxicity/neuropathy of Grade 2 or greater according to the NCI Common Toxicity Criteria Version 2.
- History of preexisting neurological disorders (grade 3 or higher by the NCI Common Toxicity Criteria; in particular, seizure disorders).
- Patients with an underlying medical condition that could be aggravated by the treatment or life threatening disease unrelated to AML as evaluated by the enrolling physician.
- Patients with active second malignancy, excluding adequately treated basal or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.
- Inability or unwillingness to comply with the treatment protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arsenic Trioxide (ATO) Plus Ascorbic acid
Arsenic Trioxide (ATO) given at 0.25 mg/kg/day intravenously for 25 days over a 35-day period. Ascorbic Acid given at 1000 mg/day intravenously every other day that ATO is given |
Arsenic Trioxide .25 mg/kg/day
Ascorbic Acid 1000 mg every other day for 25 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With a Response (Complete Remissions (CR) and Complete Remission With Incomplete Blood Count Recovery (CRi)
Time Frame: Up to 1 year
|
Complete Remission (CR): ANC >=1000/mcl, Platelet count >=100,000/mcl, Bone marrow <5% blasts.
Complete Remission with incomplete blood count recovery (CRi): Same as CR but ANC may be <1,000/mcl and/or platelet count <100,000/mcl.
Patients who failed to achieve CR or CRi after two cycles were considered treatment failures.
Patients who did not complete at least two cycles were not evaluated for response.
|
Up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Severe (Grades 3-5) Adverse Events
Time Frame: Days 1, 8, 15, 21, 28, 35 of each cycle and at end of treatment (30 days after last dose or start of new therapy)
|
Patients who received any amount of ATO plus Ascorbic Acid are included in the safety analyses.
|
Days 1, 8, 15, 21, 28, 35 of each cycle and at end of treatment (30 days after last dose or start of new therapy)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Dan Douer, MD, University of Southern California
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 9L-02-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myelogenous Leukemia
-
Masonic Cancer Center, University of MinnesotaCompletedRelapsed Acute Myelogenous Leukemia | Refractory Acute Myelogenous LeukemiaUnited States
-
Dana-Farber Cancer InstituteBoston Children's Hospital; Brigham and Women's HospitalCompletedMyelogenous Leukemia, AcuteUnited States
-
Cooperative Study Group A for HematologyCompletedACUTE MYELOGENOUS LEUKEMIAKorea, Republic of
-
Therapeutic Advances in Childhood Leukemia ConsortiumGenzyme, a Sanofi CompanyTerminatedRelapsed Acute Myelogenous LeukemiaUnited States
-
Wake Forest University Health SciencesCompleted
-
Wake Forest University Health SciencesCompleted
-
Hoffmann-La RocheCompletedNeoplasms, Myelogenous Leukemia, AcuteUnited States, Canada
-
Masonic Cancer Center, University of MinnesotaTerminatedAcute Myelogenous Leukemia | Refractory Acute Myelogenous LeukemiaUnited States
-
Kyowa Hakko Kirin Pharma, Inc.TerminatedAcute Myelogenous Leukemia (AML)United States
-
PfizerNo longer availableCD33 Positive Acute Myelogenous LeukemiaUnited States
Clinical Trials on Arsenic Trioxide (ATO)
-
Syros PharmaceuticalsSuspendedAcute Promyelocytic LeukemiaUnited States
-
Yang LiRuijin HospitalRecruitingPediatric Cancer | Li-Fraumeni Syndrome | p53 MutationsChina
-
Tehran University of Medical SciencesCompletedLeukemia, Myeloid, AcuteIran, Islamic Republic of
-
Yang LiRecruiting
-
Emory UniversityNational Cancer Institute (NCI); Teva Pharmaceuticals USA; CephalonCompletedLung Cancer | Carcinoma, Small Cell | Pulmonary Neoplasms | Pulmonary Cancer | Cancer of LungUnited States
-
Gruppo Italiano Malattie EMatologiche dell'AdultoRecruitingAcute Promyelocytic LeukemiaItaly
-
Jonsson Comprehensive Cancer CenterCelgene Corporation; CTI BioPharmaTerminatedMyelodysplastic Syndromes | LeukemiaUnited States
-
Fox Chase Cancer CenterM.D. Anderson Cancer Center; Teva Pharmaceuticals USACompletedAcute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic SyndromeUnited States
-
Northwestern UniversityCTI BioPharma; CephalonUnknownBrain and Central Nervous System TumorsUnited States
-
Ruijin HospitalRecruitingRefractory Solid TumorsChina